References
- Rodzynek J J, Urbain D, Leautaud P, Wettendorff P, Delcourt A. Antithrombin III, plasminogen and α2-antiplasmin in jaundice. Clinical usefulness and prognostic significance. Gut 1984; 25: 1050–1056
- Maisonneuve P, Sultan Y. Modification of factor VIII complex properties in patients with liver disease. J Clin Pathol 1977; 30: 221–227
- Langley P G, Hughes R D, Williams R. Increased factor VIII complex in fulminant hepatic failure. Thromb Haemostas 1985; 54: 693–696
- Ratnoff O D. Disorders of hemostasis, O D Ratnoff, C D Forbes. Grune and Stratton Inc., New York 1984; 451–471
- Sherlock S, Scheuer P. The Presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674–678
- Kaplan M M. Primary biliary cirrhosis. N Engl J Med 1987; 316: 521–528
- Cederblad G, Korsan-Bengtsen K, Olsson R. Observations of increased levels of blood coaeulation factors and other plasma proteins in chole-static liver disease. Scand J Gastroenterol 1976; 11: 391–396
- Sinclair T S, Booth N A, Penman S M, Brunt P W, Mowat N A G, Bennet N B. Protease inhibitors in liver disease. Scand J Gastroenterol 1988; 23: 62G–624
- Wiman B, Nilsson T. A new simple method for determination of C1-esterase inhibitor activity in plasma. Clin Chim Acta 1983; 128: 359–366
- Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356–1358
- Laurell C-B. Quantitative estimation of proteins by electro-phoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45–52
- Ganrot P O. Variation of the concentration of some plasma proteins in normal adults, in pregnant women and in newborns. Scand J Clin Lab Invest 1972; 29(suppl 124)83–88
- Nilsson T K. Aspects of C1 inhibitor biochemistry, and pathophysiology. Clin Rheumatol 1987; 6: 332–339
- Nilsson T K, Tomic R, Ljungberg B. Effects of high dose medroxy-progesteron acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma. Scand J Urol Nephrol 1989; 23: 11–14